These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2357842)

  • 1. C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus.
    Wild G; Watkins J; Ward AM; Hughes P; Hume A; Rowell NR
    Clin Exp Immunol; 1990 May; 80(2):167-70. PubMed ID: 2357842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation in systemic sclerosis.
    Wild G; Watkins J; Ward AM; Hughes P; Hume A; Rowell NR
    J Clin Lab Immunol; 1990 Jan; 31(1):39-41. PubMed ID: 1966983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation in patients with primary antiphospholipid syndrome.
    Oku K; Atsumi T; Bohgaki M; Amengual O; Kataoka H; Horita T; Yasuda S; Koike T
    Ann Rheum Dis; 2009 Jun; 68(6):1030-5. PubMed ID: 18625630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of complement activation products in the assessment of systemic lupus erythematosus flares.
    Porcel JM; Ordi J; Castro-Salomo A; Vilardell M; Rodrigo MJ; Gene T; Warburton F; Kraus M; Vergani D
    Clin Immunol Immunopathol; 1995 Mar; 74(3):283-8. PubMed ID: 7859418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased anaphylatoxins (C3a and C4a) in psoriatic sera.
    Ohkohchi K; Takematsu H; Tagami H
    Br J Dermatol; 1985 Aug; 113(2):189-96. PubMed ID: 3875363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
    Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
    Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma anaphylatoxin concentrations in inflammatory skin diseases.
    Terui T; Takematsu H; Kato T; Ohkohchi K; Tagami H
    Tohoku J Exp Med; 1987 Feb; 151(2):245-52. PubMed ID: 3495048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of complement measurements in the assessment of lupus activity.
    Milis L; Timmermans V; Morris CA; Pussell BA; Charlesworth JA
    Aust N Z J Med; 1992 Aug; 22(4):338-44. PubMed ID: 1445021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaphylatoxin generation in multisystem organ failure.
    Heideman M; Hugli TE
    J Trauma; 1984 Dec; 24(12):1038-43. PubMed ID: 6334754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of the anaphylatoxins C3a and C4a in patients with IgA nephropathy/Henoch-Schönlein nephritis.
    Abou-Ragheb HH; Williams AJ; Brown CB; Milford-Ward A
    Nephron; 1992; 62(1):22-6. PubMed ID: 1436286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis.
    Hack CE; Nuijens JH; Felt-Bersma RJ; Schreuder WO; Eerenberg-Belmer AJ; Paardekooper J; Bronsveld W; Thijs LG
    Am J Med; 1989 Jan; 86(1):20-6. PubMed ID: 2783358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaphylatoxin levels in human aqueous humor.
    Mondino BJ; Sumner H
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaphylatoxin formation in extracorporeal circuits.
    Chenoweth DE
    Complement; 1986; 3(3):152-65. PubMed ID: 3492330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease.
    Belmont HM; Hopkins P; Edelson HS; Kaplan HB; Ludewig R; Weissmann G; Abramson S
    Arthritis Rheum; 1986 Sep; 29(9):1085-9. PubMed ID: 3489467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of anaphylatoxin concentrations in suction blisters in patients with psoriasis.
    Ohkohchi K; Takematsu H; Tagami H
    J Invest Dermatol; 1986 Jul; 87(1):65-7. PubMed ID: 3487596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical expression of systemic lupus erythematosus in patients with C4A deficiency.
    Petri M; Watson R; Winkelstein JA; McLean RH
    Medicine (Baltimore); 1993 Jul; 72(4):236-44. PubMed ID: 8341140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients.
    Boeckler P; Meyer A; Uring-Lambert B; Goetz J; Cribier B; Hauptmann G; Lipsker D
    Clin Immunol; 2006 Nov; 121(2):198-202. PubMed ID: 16987709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity.
    Kerr LD; Adelsberg BR; Schulman P; Spiera H
    Arthritis Rheum; 1989 Nov; 32(11):1406-13. PubMed ID: 2818657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of three separate anaphylatoxins from complement-activated human serum.
    Hugli TE; Gerard C; Kawahara M; Scheetz ME; Barton R; Briggs S; Koppel G; Russell S
    Mol Cell Biochem; 1981 Dec; 41():59-66. PubMed ID: 6977086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low copy numbers of complement C4 and homozygous deficiency of C4A may predispose to severe disease and earlier disease onset in patients with systemic lupus erythematosus.
    Jüptner M; Flachsbart F; Caliebe A; Lieb W; Schreiber S; Zeuner R; Franke A; Schröder JO
    Lupus; 2018 Apr; 27(4):600-609. PubMed ID: 29050534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.